Citations

Clear

3942 citation(s) found for "To, Van".

Three‐hundred and sixty degrees of surgical approaches to the maxillary sinus
Rezende, Natalia , Leonel, Luciano, Peris‐Celda, Maria , Rezende, Natália C, Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van , Choby, Garret

Mayo Clinic

World Journal of Otorhinolaryngology - Head and Neck Surgery | May 10, 2022 | Volume: 8 | Issue: 1 | Pages: 42-53

10.1002/wjo2.12 | PMID 35619930 Get It

AbstractObjectivesTo demonstrate three‐hundred and sixty degrees of maxillary sinus (MS) surgical approaches using cadaveric dissections, highlighting the step‐by‐step anatomy of each procedure.MethodsTwo latex‐injected cadaveric specimens were utilized to perform surgical dissections to demonstrate different approaches to the MS. The procedures were documented with macroscopic images and endoscopic pictures.ResultsDissections were performed to approach the MS medially (endoscopic maxillary antrostomy and ethmoidectomy), anteriorly (Caldwell–Luc), superiorly (transconjunctival/transorbital approach), inferiorly (transpalatal approach), and posterolaterally (preauricular hemicoronal approach).ConclusionA number of approaches have been described to address pathology in the MS. Surgeons should be familiar with indications, limitations, and surgical anatomy from different perspectives to approach the MS. This paper illustrates anatomic approaches to the MS with detailed step‐by‐step cadaveric dissections and case examples.
Artificial intelligence—electrocardiography to detect atrial fibrillation: trend of probability before and after the first episode
Christopoulos, Georgios , Houten, Holly K. Van , Carter, Rickey E. , López-Jiménez, Francisco , Friedman, Paul A. , Lopez-Jimenez, Francisco , Kapa, Suraj , Carter, Rickey E , Attia, Zachi I. , Yao, Xiaoxi , Kapa, Suraj , Noseworthy, Peter A.

Mayo Clinic

European Heart Journal - Digital Health | May 9, 2022 | Volume: 3 | Issue: 2 | Pages: 228-235

10.1093/ehjdh/ztac023 | PMID 36713006 Get It

Abstract Aims Artificial intelligence (AI) enabled electrocardiography (ECG) can detect latent atrial fibrillation (AF) in patients with sinus rhythm (SR). However, the change of AI-ECG probability before and after the first AF episode is not well characterized. We sought to characterize the temporal trend of AI-ECG AF probability around the first episode of AF. Methods and results We retrospectively studied adults who had at least one ECG in SR prior to an ECG that documented AF. An AI network calculated the AF probability from ECGs during SR (positive defined >8.7%, based on optimal sensitivity and specificity). The AI-ECG probability was reported prior to and after the first episode of AF and stratified by age and CHA2DS2-VASc score. Mixed effect models were used to assess the rate of change between time points. A total of 59 212 patients with 544 330 ECGs prior to AF and 413 486 ECGs after AF were included. The mean time between the first positive AI-ECG and first AF was 5.4 ± 5.7 years. The mean AI-ECG probability was 19.8% 2–5 years prior to AF, 23.6% 1–2 years prior to AF, 34.0% 0–3 months prior to AF, 40.9% 0–3 months after AF, 35.2% 1–2 years after AF, and 42.2% 2–5 years after AF (P < 0.001). The rate of increase prior to AF was higher for age >50 years CHA2DS2-VASc score ≥4. Conclusion The AI-ECG probability progressively increases with time prior to the first AF episode, transiently decreases 1–2 years following AF and continues to increase thereafter.
Distributed brain co-processor for tracking spikes, seizures and behaviour during electrical brain stimulation
Sladky, Vladimir , Nejedlý, Petr , Brinkmann, Benjamin H. , Kim, Inyong , Louis, Erik K. St. , Gregg, Nicholas M. , Lundstrom, Brian N. , Crowe, Chelsea M. , Attia, Tal Pal , Crepeau, Daniel, Balzekas, Irena , Wheeler, Lydia , Cook, Mark , Sturges, Beverly K., Leyde, Kent, Miller, Kai J. , Křemen, Václav , Mívalt, Filip , Brinkmann, Benjamin H , St Louis, E K , Gregg, Nicholas M , Lundstrom, Brian Nils , Pal Attia, Tal , Marks, Victoria S , Wheeler, Lydia P, Van Gompel, Jamie J , Kremen, Vaclav , Cook, Mark J , Marks, Victoria S. , Cimbálník, Jan , Janča, Radek , Gompel, Jamie J. Van , Denison, Timothy , Worrell, Gregory A.

Mayo Clinic

Brain Communications | May 6, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcac115 | PMID 35755635 Get It

Abstract Early implantable epilepsy therapy devices provided open-loop electrical stimulation without brain sensing, computing, or an interface for synchronized behavioural inputs from patients. Recent epilepsy stimulation devices provide brain sensing but have not yet developed analytics for accurately tracking and quantifying behaviour and seizures. Here we describe a distributed brain co-processor providing an intuitive bi-directional interface between patient, implanted neural stimulation and sensing device, and local and distributed computing resources. Automated analysis of continuous streaming electrophysiology is synchronized with patient reports using a handheld device and integrated with distributed cloud computing resources for quantifying seizures, interictal epileptiform spikes and patient symptoms during therapeutic electrical brain stimulation. The classification algorithms for interictal epileptiform spikes and seizures were developed and parameterized using long-term ambulatory data from nine humans and eight canines with epilepsy, and then implemented prospectively in out-of-sample testing in two pet canines and four humans with drug-resistant epilepsy living in their natural environments. Accurate seizure diaries are needed as the primary clinical outcome measure of epilepsy therapy and to guide brain-stimulation optimization. The brain co-processor system described here enables tracking interictal epileptiform spikes, seizures and correlation with patient behavioural reports. In the future, correlation of spikes and seizures with behaviour will allow more detailed investigation of the clinical impact of spikes and seizures on patients.
FC044: Heterozygous Variants in Kinase Domain of NEK8 cause an Autosomal-Dominant Ciliopathy
Claus, Laura R. , Stallworth, Jennifer L., Turner, Joshu, Hawks, Alexandra L. , May, Melanie , Louie, Raymond J. , Silver, Josh, Lerner-Ellise, Jordan, Morel, Chantal F. , Mighton, Chloe, Ziegler, Alban , Larsen, Martin J. , Lilien, Marc, Obeidová, Lena , Senum, Sarah R. , Rogers, Curtis , Duran, Karen, Peters, Edith, Senum, Sarah R , Jaarsveld, Richard H. van , Turner, Joshua L. , Flanagan‐Steet, Heather R. , Barakat, Tahsin Stefan , Dahan, Karin , Demoulin, Nathalie , Goffin, Eric Jean , Hertz, Jens Michael , Olinger, Eric , Sayer, John A , Seeman, Tomáš , Hanna, Christian , Harris, Peter C. , Mason, Jennifer M. , Haaften, Gijs W van , Eerde, Albertien M. van , Steet, Richard

Mayo Clinic

Nephrology Dialysis Transplantation | May 5, 2022 | Volume: 37 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfac104.004 Get It

Abstract BACKGROUND AND AIMS NEK8/NPHP9 encodes a protein that localizes to the primary cilium. Biallelic NEK8 variants are known to cause multiorgan developmental defects, including kidney cystic dysplasia and extensive extra-renal defects, with heterozygous carrier parents being asymptomatic [1]. This autosomal recessive inheritance is the most common inheritance mode for ciliopathies. Complementary to this, we now propose a dominant negative effect for specific heterozygous NEK8 missense variants in the kinase domain resulting in an autosomal-dominant ciliopathy. METHOD We performed genetic testing in patients from several medical centers. To explore the consequences of the identified NEK8 variants, we are performing cilia staining assays in patients' skin fibroblast and kidney cells, as well as in mIMCD3 cells overexpressing the identified variants. Furthermore, we are examining the impact of the NEK8 variants on replication stress response. RESULTS We identified three distinct heterozygous NEK8 variants in 12 families (Table 1), all leading to missense alterations in the kinase domain. Interestingly the p.Arg45Trp variant is a recurrent variant we detected in 10 unrelated families. All patients have a kidney phenotype that varies from mild focal segmental glomerulosclerosis to prenatal presentation with polycystic kidneys. Most patients have kidney failure needing kidney replacement therapy at varying ages of onset. In all patients, we thoroughly checked whether a second variant could be found. Furthermore, the large symptomatic family and de novo occurrences favor a dominant inheritance mode. Our preliminary results from functional studies show abnormal primary cilia formation in serum-starved cells as well as increased replication stress. CONCLUSION We present the first evidence for a pathogenic effect of heterozygous NEK8 variants. Remarkably our patients present with a kidney limited phenotype as compared to the multiorgan defects found in patients with biallelic variants. This reveals a new mode of inheritance for NEK8 variants and expands genotype-phenotype correlations for this gene.
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations
Aertgeerts, Bert , Vandvik, Per Olav , Al‐Ansary, Lubna A. , Driel, Mieke van , Agoritsas, Thomas , Lytvyn, Lyubov , Heen, Anja Fog , Ramaekers, Dirk , Okwen, Patrick Mba, Zhu, Ye , Dawson, Annabel, Ovidiu, Mersa Caius, Vanbrabant, Willy, Li, Sheyu , Riaz, Irbaz Bin , Li, Sheyu , Hao, Qiukui , Guyatt, Gordon , Bekkering, Geertruida Elsiena , Khan, Safi U. , Rodondi, Nicolas , Jackson, Rod , Reny, Jean‐Luc , Assendelft, Willem JJ , Spencer, Frederick A. , Siemieniuk, Reed Alexander Cunningham , Zhao, Qian , Delvaux, Nicolas

Mayo Clinic

BMJ | May 4, 2022 | Volume: 377 | Issue: No issue available | Pages: e069066

10.1136/bmj-2021-069066 | PMID 35508320 Get It

Abstract Clinical question In adults with low density lipoprotein (LDL) cholesterol levels >1.8 mmol/L (>70 mg/dL) who are already taking the maximum dose of statins or are intolerant to statins, should another lipid-lowering drug be added, either a proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor or ezetimibe, to reduce the risk of major cardiovascular events? If so, which drug is preferred? Having decided to use one, should we add the other lipid-lowering drug? Current practice Most guidelines emphasise LDL cholesterol targets in their recommendations for prescribing PCSK9 inhibitors and/or ezetimibe in adults at high risk of experiencing a major adverse cardiovascular event. However, to achieve these goals in very high risk patients with statins alone is almost impossible, so physicians are increasingly considering other lipid-lowering drugs solely for achieving LDL cholesterol treatment goals rather than for achieving important absolute cardiovascular risk reduction. Most guidelines do not systematically assess the cardiovascular benefits of adding PCSK9 inhibitors and/or ezetimibe for all risk groups across primary and secondary prevention, nor do they report, in accordance with explicit judgments of assumed patients’ values and preferences, absolute benefits and harms and potential treatment burdens. Recommendations The guideline panel provided mostly weak recommendations, which means we rely on shared decision making when applying these recommendations. For adults already using statins, the panel suggests adding a second lipid-lowering drug in people at very high and high cardiovascular risk but recommends against adding it in people at low cardiovascular risk. For adults who are intolerant to statins, the panel recommends using a lipid-lowering drug in people at very high and high cardiovascular risk but against adding it in those at low cardiovascular risk. When choosing to add another lipid-lowering drug, the panel suggests ezetimibe in preference to PCSK9 inhibitors. The panel suggests further adding a PCSK9 inhibitor to ezetimibe for adults already taking statins at very high risk and those at very high and high risk who are intolerant to statins. How this guideline was created An international panel including patients, clinicians, and methodologists produced these recommendations following standards for trustworthy guidelines and using the GRADE approach. The panel identified four risk groups of patients (low, moderate, high, and very high cardiovascular risk) and primarily applied an individual patient perspective in moving from evidence to recommendations, though societal issues were a secondary consideration. The panel considered the balance of benefits and harms and burdens of starting a PCSK9 inhibitor and/or ezetimibe, making assumptions of adults’ average values and preferences. Interactive evidence summaries and decision aids accompany multi-layered recommendations, developed in an online authoring and publication platform ( www.magicapp.org ) that also allows re-use and adaptation. The evidence A linked systematic review and network meta-analysis (14 trials including 83 660 participants) of benefits found that PCSK9 inhibitors or ezetimibe probably reduce myocardial infarctions and stroke in patients with very high and high cardiovascular risk, with no impact on mortality (moderate to high certainty evidence), but not in those with moderate and low cardiovascular risk. PCSK9 inhibitors may have similar effects to ezetimibe on reducing non-fatal myocardial infarction or stroke (low certainty evidence). These relative benefits were consistent, but their absolute magnitude varied based on cardiovascular risk in individual patients (for example, for 1000 people treated with PCSK9 inhibitors in addition to statins over five years, benefits ranged from 2 fewer strokes in the lowest risk to 21 fewer in the highest risk). Two systematic reviews on harms found no important adverse events for these drugs (moderate to high certainty evidence). PCSK9 inhibitors require injections that sometimes result in injection site reactions (best estimate 15 more per 1000 in a 5 year timeframe), representing a burden and harm that may matter to patients. The MATCH-IT decision support tool allows you to interact with the evidence and your patients across the alternative options: https://magicevidence.org/match-it/220504dist-lipid-lowering-drugs/ . Understanding the recommendations The stratification into four cardiovascular risk groups means that, to use the recommendations, physicians need to identify their patient’s risk first. We therefore suggest, specific to various geographical regions, using some reliable risk calculators that estimate patients’ cardiovascular risk based on a mix of known risk factors. The largely weak recommendations concerning the addition of ezetimibe or PCSK9 inhibitors reflect what the panel considered to be a close balance between small reductions in stroke and myocardial infarctions weighed against the burdens and limited harms. Because of the anticipated large variability of patients’ values and preferences, well informed choices warrant shared decision making. Interactive evidence summaries and decision aids linked to the recommendations can facilitate such shared decisions. The strong recommendations against adding another drug in people at low cardiovascular risk reflect what the panel considered to be a burden without important benefits. The strong recommendation for adding either ezetimibe or PCSK9 inhibitors in people at high and very high cardiovascular risk reflect a clear benefit. The panel recognised the key uncertainty in the evidence concerning patient values and preferences, namely that what most people consider important reductions in cardiovascular risks, weighed against burdens and harms, remains unclear. Finally, availability and costs will influence decisions when healthcare systems, clinicians, or people consider adding ezetimibe or PCSK9 inhibitors.
Postprandial symptoms in patients with symptoms of gastroparesis: roles of gastric emptying and accommodation
Parkman, Henry P. , Natta, Mark L. Van , Maurer, Alan H. , Koch, Kenneth L. , Grover, Madhusudan , Malik, Zubair , Sarosiek, Irene , Bulat, Robert, Shulman, Robert J. , Farrugia, Gianrico , Miriel, Laura , Tonascia, James , Hamilton, Frank A., Pasricha, Pankaj J. , McCallum, Richard W. , Farrugia, Gianrico , Parkman, H P , Abell, Thomas L. , Kuo, Braden

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | May 3, 2022 | Volume: 323 | Issue: 1 | Pages: G44-G59

10.1152/ajpgi.00278.2021 | PMID 35502871 Get It

Patients with delayed and normal gastric emptying (GE) had similar symptom profiles during gastric emptying scintigraphy (GES). Idiopathic patients with symptoms of gastroparesis had less gastric retention by GES; but more symptoms after GES meal and after water load satiety test (WLST) compared with diabetic patients. In patients with symptoms of gastroparesis, symptoms after WLST increased with decreasing water consumption. Early satiety and loss of appetite were associated with decreased water consumption during WLST. Thus, impaired accommodation and perhaps visceral hypersensitivity are important in explaining postprandial symptoms in gastroparesis.
Wide Individual Heterogeneity in Antigen-Specific Immunity After Coronavirus Disease 2019 (COVID-19) Infection
Marty, Paige K. , Shah, Manisha , Keulen, Virginia Van, Erskine, Courtney L. , Peikert, T., Escalante, Patricio , Keulen, Virginia P. Van

Mayo Clinic

A33. BIOMARKERS, ALLERGY AND IMMUNE RESPONSES IN COVID-19 | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A1285-A1285

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1285 Get It

Immune Profiling and Paraffin Tissue Immunostaining in a Case of Subclinical Pulmonary Tuberculoma
Marty, Paige K. , Keulen, Virginia Van, Erskine, Courtney L. , Roden, Anja C. , Peikert, T., Escalante, Patricio , Shah, Meera , Keulen, Virginia P. Van , Wilson, J.

Mayo Clinic

A59. TUBERCULOSIS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A1881-A1881

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1881 Get It

Genetic Regulators of Sputum Mucin Concentration Revealed by GWAS and Their Associations with Chronic Bronchitis and Acute Exacerbations of COPD
Radicioni, Giorgia , Garudadri, S., Curtis, J.L., Krishnan, J.A., Wan, E.S., Silverman, Edwin K. , Hastie, Annette T. , Ortega, Victor E. , Christenson, S., Li, Yingying , Cho, M.H., Kelada, Samir N. P. , Buren, Eric C. Van , O’Neal, Wanda K. , Dang, Hong , Kasela, Silva , Curtis, J.L., Han, MeiLan King , Lappalainen, Tuuli , Li, Y., Cho, M.H. , Kesımer, Mehmet

Mayo Clinic

C66. COPD: GENETICS, GENOMICS, AND EPIGENETICS | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A4666-A4666

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4666 Get It

Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients Receiving B-Cell Targeted Therapy
Marty, Paige K. , Shah, Manisha H. , Keulen, Virginia Van, Erskine, Courtney L. , Theel, Elitza S. , Escalante, Patricio , Peikert, T., Keulen, Virginia P. Van , Zeng, Hu , Specks, Ulrich

Mayo Clinic

C13. IMMUNE RESPONSES AND POTENTIAL INFLAMMATORY BIOMARKERS IN SARS-CoV-2 INFECTION | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A3687-A3687

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3687 Get It